



110 West Cliff Avenue  
Spokane, WA 99204

**PATHOLOGY ASSOCIATES  
MEDICAL LABORATORIES**

509.755.8600  
800.541.7891

# TEST ALERT

Number 252, June 17, 2003

The following tables reflect revisions only; other existing data remain unchanged.

<b>Test Method GA Workpar / SQ Code CPT Code(s)</b>	<b>Specimen Requirements</b>	<b>Reference Ranges</b>	<b>Comments Effective Date</b>
ACETYLCHOLINE RECEPTOR AB PANEL ACHRPN / ACHRPN	2 mL serum (red top tube). Separate serum from cells ASAP and put in separate plastic tube. Store and transport refrigerated.		Min. amt: 1.5 mL. Unacceptable conditions: severely lipemic, contaminated, or hemolyzed samples. Stability: 2 hours at room temperature, 1 week refrigerated, 1 month frozen (avoid multiple freeze/thaw cycles). Effective 6-30-03.
ACETYLCHOLINE RECEPTOR BINDING AB AR-AB / ACETYL	1 mL serum (red top tube). Separate serum from cells and put in separate plastic tube. Store and transport refrigerated.		Min. amt: 0.5 mL. Unacceptable conditions: severely lipemic, contaminated, or hemolyzed samples. Stability: 2 hours at room temperature, 7 days refrigerated, 1 month frozen (avoid multiple freeze/thaw cycles). Note: Approximately 10% of individuals with confirmed myasthenia gravis have no measurable binding, blocking or modulating antibody. Effective 6-30-03.
ACETYLCHOLINE RECEPTOR BLOCKING AB AR.AB.BLOCK / ARAB	1 mL serum (red top tube). Separate serum from cells and put in separate plastic tube. Store and transport refrigerated.		Min. amt: 0.5 mL. Unacceptable conditions: severely lipemic, contaminated, or hemolyzed samples. Stability: 2 hours at room temperature, 7 days refrigerated, 1 month frozen (avoid multiple freeze/thaw cycles). Effective 6-30-03.
ACETYLCHOLINE RECEPTOR MODULATING AB ACHRMO / ACHRMO	2 mL serum (red top tube). Separate serum from cells ASAP and put in separate plastic tube. Store and transport refrigerated.		Min. amt: 0.8 mL. Unacceptable conditions: severely lipemic, contaminated, or hemolyzed samples. Stability: 2 hours at room temperature, 1 week refrigerated, 1 month frozen (avoid multiple freeze/thaw cycles). Effective 6-30-03.
ALK PHOS, ISO [ARUP] Kinetic Heat Inactivation/ Enzymatic AKPIAR / AKPIAR			Effective 6-30-03.

Test Method GA Workpar / SQ Code CPT Code(s)	Specimen Requirements	Reference Ranges	Comments Effective Date
ANTIBIOTIC LEVEL ANTIBIOTIC / ALEVEL	3 mL frozen serum (red top tube) or body fluid. Aseptically separate serum ASAP and freeze in sterile plastic tube. Store and transport frozen. Due to the methodology used for this assay, the presence of other antimicrobial agents may interfere and be measured in combination with the requested antimicrobial agent. Therefore, it is essential that all antimicrobial agents (including dosage, route of administration, and time of administration) be indicated on the request. For Amphotericin B level, protect from light with an amber tube or foil wrap.		Effective 6-30-03.
ARYLSULFATASE A, URINE Colorimetric/Kinetic ARYSUQ / ARYSUQ			Method change only. Effective 6-30-03.
BCL-2/SH T(14; 18) BY PCR BCL2FL / BCL2FL 83891, 83892, 83898×4, 83894×3, 83912			CPT code changes only. Effective 6-30-03.
BILE ACIDS, TOTAL CONJUGATED BILE ACIDS / BILEA	1 mL serum (red top tube). Separate serum from cells and put in separate plastic tube. Patient must be fasting for a minimum of 8 hours prior to collection. Store and transport refrigerated.	Bile Acids Fasting 0.0-10.0 µmol/L	Min. amt: 0.3 mL. Unacceptable conditions: grossly hemolyzed or lipemic samples. Stability: 8 hours at room temperature, 2 weeks refrigerated, 6 months frozen. Effective 6-30-03.
COXSACKIE B VIRUS AB COX B / COXB	3 mL serum (red top tube). Separate serum from cells ASAP and place in separate plastic tube. Store and transport refrigerated. Paired sera specimens are advised. Please indicate source.		Min. amt: 2 mL. Other acceptable specimens: CSF refrigerated or frozen. Unacceptable conditions: plasma samples. Stability: 8 hours at room temperature, 3 days refrigerated, 6 weeks frozen. Effective 6-30-03.
CREATINE KREAT / KREAT	5 mL serum (red top tube). Separate samples must be submitted when multiple tests are ordered. Store and transport refrigerated.		Min. amt: 2.5 mL. Unacceptable conditions: samples at room temperature. Effective 6-30-03.
ECHOVIRUS AB ECHO / ECHO	3 mL serum (red top tube). Separate serum from cells ASAP and place in separate plastic tube. Store and transport refrigerated. Paired sera specimens are advised. Please indicate source.		Other acceptable specimens: CSF refrigerated or frozen. Unacceptable conditions: plasma samples. Stability: 8 hours at room temperature, 3 days refrigerated, 6 weeks frozen. Effective 6-30-03.

Test Method GA Workpar / SQ Code CPT Code(s)	Specimen Requirements	Reference Ranges	Comments Effective Date
ALBUMIN, GLYCATED Boronate Aff Chrom/Turbid Immuno GLYCOALBUMIN / GLYALB		Albumin, Glycated 1.3-4.6 %	Effective 6-30-03.
MTHFR BY PCR MTHFR / MTHFR	5 mL EDTA whole blood (lavender top tube). Store and transport refrigerated. DO NOT FREEZE. Consent form is recommended.		Min. amt: 3 mL. Other acceptable specimens: ACD, sodium citrate or sodium heparin whole blood (yellow, light blue, or green top tube). Unacceptable conditions: serum, plasma, frozen whole blood, clotted blood, and severely hemolyzed samples. Stability: 24 hours at room temperature, 5 days refrigerated, unacceptable frozen. Effective 6-30-03.
ENTAMOEBA HISTOLYTICA AB, IGG AM-AB / AMOEBA		Analyte Specific Reagents (ASR) are used in many laboratory tests necessary for standard medical care and generally do not require U.S. Food and Drug Administration approval. This test was developed and its performance characteristics determined by ARUP Laboratories, Inc. It has not been approved by the U.S. Food and Drug Administration. This test should not be regarded as investigational or for research use.	Compliance statement added. Effective 6-30-03.
CHOLINESTERASE, PLASMA & RBC CHESCR / CHESCR		Pseudocholinesterase, Plasma 2.9-7.1 U/mL Pseudocholinesterase, RBC 7.9-17.1 U/mL Pseudocholinesterase, RBC/HGB Ratio 25-52 U/gHgb Pseudocholinesterase, Plasma Ellman 1.0-2.4 U/mL Pseudocholinesterase, RBC Ellman 2.4-5.9 U/mL	Effective 6-30-03.
MYOGLOBIN, URINE (NO PIGMENT), QUANT Electrochemiluminescent Immunoassay MYOGLOBIN-U / MGNPUR	1 mL urine, random or 24 hours. Refrigerate during collection. Adjust pH to 8.0-9.0 immediately after collection. Record total volume and collection interval on transport tube and request form. Store and transport refrigerated.		Min. amt: 0.5 mL. Stability: 1 hour at room temperature, 3 days refrigerated, 1 month frozen. Effective 6-30-03.
POLIOVIRUS AB POLIO.AB / POLIOV	1 mL serum (red top tube). Separate serum from cells ASAP and put in separate plastic tube. Store and transport refrigerated. Paired sera are advised. Please indicate source.	Source Poliovirus Ab Type 1 LT 1:10 Poliovirus Ab Type 2 LT 1:10 Poliovirus Ab Type 3 LT 1:10	Min. amt: 0.5 mL. Other acceptable specimens: CSF refrigerated or frozen. Unacceptable conditions: plasma samples. Stability: 8 hours at room temperature, 3 days refrigerated, 6 weeks frozen. Effective 6-30-03.

<b>Test Method</b> <b>GA Workpar / SQ Code</b> <b>CPT Code(s)</b>	<b>Specimen Requirements</b>	<b>Reference Ranges</b>	<b>Comments</b> <b>Effective Date</b>																																
PSA, FREE PERCENT [ARUP] Electrochemiluminescent Immunoassay PSAFAR / PSAFAR	1 mL frozen serum (red top tube). Collect on ice. Separate serum from cells, put in separate plastic tube, and freeze. Store and transport frozen.	<table border="0"> <tr> <td>PSA-Free</td> <td></td> <td>ng/mL</td> <td></td> </tr> <tr> <td>PSA</td> <td>0.0-4.0</td> <td>ng/mL</td> <td></td> </tr> <tr> <td>PSA-Percent Free</td> <td></td> <td>%</td> <td></td> </tr> </table> <p>ARUP uses the Roche Modular E170 Free PSA method in conjunction with the Roche Modular E170 PSA method to determine the free PSA percentage.</p> <p>The free PSA percentage is an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 and older with a total PSA between 3 and 10 ng/mL and negative digital rectal examination findings. Prostatic biopsy is required for the diagnosis of cancer.</p> <p>Probability of finding cancer on needle biopsy by age in years:</p> <table border="0"> <tr> <td>% Free PSA</td> <td>50-59 yrs</td> <td>60-69 yrs</td> <td>70 or more</td> </tr> <tr> <td>10%</td> <td>49.2</td> <td>57.5</td> <td>64.5</td> </tr> <tr> <td>11-18%</td> <td>26.9</td> <td>33.9</td> <td>40.8</td> </tr> <tr> <td>19-25%</td> <td>18.3</td> <td>23.9</td> <td>29.7</td> </tr> <tr> <td>GT 25%</td> <td>9.1</td> <td>12.2</td> <td>15.8</td> </tr> </table> <p>Other factors may help determine the actual risk of prostate cancer in individual patients.</p> <p>The Roche Modular E170 PSA method is used. Results obtained with different assay methods or kits cannot be used interchangeably. The Roche Modular E170 PSA method is approved for use in the detection of prostate cancer when used in conjunction with a digital rectal exam in men age 50 and older. The Roche Modular E170 PSA method is also indicated for serial measurement of PSA to aid in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can only suggest the presence of prostate cancer until biopsy is performed. PSA concentrations can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy men or men with non-prostatic carcinoma.</p>	PSA-Free		ng/mL		PSA	0.0-4.0	ng/mL		PSA-Percent Free		%		% Free PSA	50-59 yrs	60-69 yrs	70 or more	10%	49.2	57.5	64.5	11-18%	26.9	33.9	40.8	19-25%	18.3	23.9	29.7	GT 25%	9.1	12.2	15.8	Min. amt: 0.5 mL. Other acceptable specimens: heparinized or EDTA plasma. Unacceptable conditions: hemolyzed samples. Stability: 8 hours at room temperature, 24 hours refrigerated, 3 months frozen. Effective 6-30-03.
PSA-Free		ng/mL																																	
PSA	0.0-4.0	ng/mL																																	
PSA-Percent Free		%																																	
% Free PSA	50-59 yrs	60-69 yrs	70 or more																																
10%	49.2	57.5	64.5																																
11-18%	26.9	33.9	40.8																																
19-25%	18.3	23.9	29.7																																
GT 25%	9.1	12.2	15.8																																
PSEUDOCHOLINESTERASE + DIBUCAINE PSEUDO-DIB / PSEUDD		<table border="0"> <tr> <td>Pseudocholinesterase</td> <td>2900-7100</td> <td>U/L</td> <td></td> </tr> <tr> <td>Dibucaine #</td> <td>GT 75</td> <td>%</td> <td></td> </tr> <tr> <td>Phenotype</td> <td></td> <td></td> <td></td> </tr> </table>	Pseudocholinesterase	2900-7100	U/L		Dibucaine #	GT 75	%		Phenotype				Effective 6-30-03.																				
Pseudocholinesterase	2900-7100	U/L																																	
Dibucaine #	GT 75	%																																	
Phenotype																																			
PSEUDOCHOLINESTERASE, TOTAL CHEP / CHEP		Pseudocholinesterase, Total 2900-7100 U/L	Effective 6-30-03.																																
RUBELLA ICMA RUBELLA / RUBEG  Also: OB.PANEL / OBPAN TORCHG / TORCHG TORHGM / TORGM RPR/RUB RUBPM / RUBPM			Other acceptable specimens: EDTA or heparin plasma (lavender or green top tube). Effective immediately.																																

<b>Test Method</b> <b>GA Workpar / SQ Code</b> <b>CPT Code(s)</b>	<b>Specimen Requirements</b>	<b>Reference Ranges</b>	<b>Comments</b> <b>Effective Date</b>
UREAPLASMA/MYCOPLASMA CULTURE UMC / UMC	Urine, urethral or cervical swab, semen, biopsy tissue or body fluid in M4 or Ureaplasma transport media. For neonates, use CSF, tracheal, or NP aspirate or swab in M4 (do not use M4RT) or Ureaplasma transport media. Use leakproof sterile container if media is not available. If transport time will exceed 24 hours, freeze sample at -70°C and transport on dry ice. Indicate specimen source.		M4 transport media is available from the PAML Supply Dept. Unacceptable conditions: other transport media, including M4RT, nonpatient samples, and dry swabs. Stability: 8 hours at room temperature, 24 hours refrigerated, 1 month frozen (-70°C). Effective 6-30-03.
FREE PSA ECLIA FPSA / RATPSA	1 mL serum (red top tube). Separate serum from cells and put in separate plastic tube. Store and transport refrigerated.	Total PSA 0-54 yrs 0.00-2.50 ng/mL 55-59 yrs 0.00-3.40 60-64 yrs 0.00-4.10 65-69 yrs 0.00-5.10 70+ yrs 0.00-5.60  Free PSA (ng/mL) Free/Total PSA Ratio (%) Ratios GT 20% suggest benign. Ratios between 10% and 20% show substantial overlap in benign and malignant conditions. Ratios LT 10% suggest carcinoma. The ratio is most clinically useful in the total PSA range 4-10 ng/mL. This is now an FDA-approved procedure. For purposes of calculating the PSA ratio, the total PSA and the free PSA were measured by the same analytical method (Roche Diagnostics). This procedure will ensure the most accurate free PSA ratio. PAML's routine total PSA method is from Bayer Diagnostics, and those results may show slight differences from results obtained with the Roche method. The free PSA ratio is useful in differentiating between benign prostatic hypertrophy and prostatic carcinoma. Serial monitoring of patients should be done with total PSA measurements performed with the routine Bayer method.	Min Amt: 0.5 mL. Other acceptable specimens: lithium heparin or EDTA plasma. Unacceptable conditions: heat-inactivated samples, and samples stabilized with azide. Minimum detectable concentration is 0.03 ng/mL for PSA and 0.02 ng/mL for Free PSA. Stability: 5 days refrigerated, 3 months frozen. Effective 6-25-03.
H. PYLORI IGG, IGA & IGM AB HPYAGM / HPYAGM		H. pylori IgG 12.5 or less U/mL H. pylori IgM 30.0 or less U/mL H. pylori IgA 12.5 or less U/mL	All interpretive criteria and comments remain as announced in TA 251. Effective immediately.